Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease

Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease

Satoshi Igawa,1 Noriko Nishinarita,1 Akira Takakura,1 Takahiro Ozawa,1 Shinya Harada,1 Seiichiro Kusuhara,1 Hideyuki Niwa,2 Shinji Hosotani,1 Hideyuki Sone,1 Yoshiro Nakahara,1,3 Tomoya Fukui,1 Hisashi Mitsufuji,4 Masanori Yokoba,5 Masaru Kubota,1 Masato Katagiri,5 Jiichiro Sasaki,6 Katsuhiko Naoki1...

Full description

Bibliographic Details
Main Authors: Igawa S, Nishinarita N, Takakura A, Ozawa T, Harada S, Kusuhara S, Niwa H, Hosotani S, Sone H, Nakahara Y, Fukui T, Mitsufuji H, Yokoba M, Kubota M, Katagiri M, Sasaki J, Naoki K
Format: Article
Language:English
Published: Dove Medical Press 2018-12-01
Series:Cancer Management and Research
Subjects:
Interstitial Lung Disease
Non-Small cell lung cancer
Carboplatin
Nab-Paclitaxel
Online Access:https://www.dovepress.com/real-world-evaluation-of-carboplatin-plus-a-weekly-dose-of-nab-paclita-peer-reviewed-article-CMAR

Internet

https://www.dovepress.com/real-world-evaluation-of-carboplatin-plus-a-weekly-dose-of-nab-paclita-peer-reviewed-article-CMAR

Similar Items